|
New Products
- Crisaborole (Staquis) is a competitive inhibitor of cyclic adenosine monophosphate (cAMP) at the phosphodiesterase-4 (PDE-4) catalytic site resulting in increased intracellular cAMP levels. As a PDE-4 inhibitor, crisaborole suppresses inflammation and secretion of certain cytokines, such as tumour necrosis factor-α, from the peripheral blood mononuclear cells. Staquis is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older. Staquis ointment contains 20 mg/g crisaborole and is available in a pack size of 60 g.
- Patiromer (sorbitex calcium) (Veltassa) is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol complex as a counterion. It increases faecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. Veltassa is indicated for the treatment of hyperkalaemia in adults. Veltassa powder for oral suspension contains 8.4 g patiromer and is available in a pack size of 30 sachets.
|
|
|
New Indications
- Certolizumab pegol (rbe) (Cimzia) is now indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) change, who have had an inadequate response to, or are intolerant to, nonsteroidal anti‐inflammatory drugs (NSAIDs).
- Dolutegravir (Na) (Tivicay) is now indicated for the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in children over 6 years of age.
- Progesterone (Oripro, Utrogestan 200) is now indicated for the prevention of preterm birth in singleton pregnancies at risk due to shortened cervix (midtrimester sonographic cervix ≤ 25 mm) and/or where there is a history of spontaneous preterm birth.
|
|
|
New Contraindications
- Fluorouracil (DBL Fluorouracil, Fluorouracil Ebewe) must not be taken within 4 weeks of treatment with brivudine, sorivudine or their chemically related analogues.
- Hydromorphone hydrochloride (Jurnista) is now contraindicated with significant respiratory depression.
- Progesterone (Oripro) is now contraindicated with ectopic pregnancy.
|
|
|
This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.
|
|
|
|
|
|
|
|
|
